Operations-Driven Life Sciences Investors

Gurnet Point Capital invests in companies with scientifically de-risked life science products with the goal of bringing safe and effective treatments to market, positively impacting patient outcomes and generating outsized investor returns*.

/ / /

Active ownership approach

We drive these returns through our active ownership approach, taking control positions to apply the skills and experience of our differentiated investment and operations team that efficiently move our portfolio companies through key value inflection points.

Gurnet Point Capital (GPC) defines De-Risked life science companies which have mitigated the scientific risk in their primary product or service​. Typically, products are post Phase 3 data, when toxicology data are available, and the treatment is proven safe​. No investment made by GPC, not any commitment to a fund managed by GPC, is without risk.